Both of these nuclear receptors have increased expression in breast cancer [38] and ovarian cancer [39], while in neuroblastoma ESRRA expression has been shown to increase HIF2A expression and correlates with poor survival [40]. This evidence concerns the gene EPAS1 and breast cancer.